Search Results

The November layoffs are the second known workforce reduction this year for Marinus Pharmaceuticals, which previously announced disappointing Phase III results for ganaxolone in two clinical trials.

Conatus Pharmaceuticals Inc. (NASDAQ: CNAT) today announced the appointment of Kathleen D. Scott to the Conatus Board of Directors as an additional independent member.

Conatus Pharmaceuticals Inc. announced that Institutional Shareholder Services Inc. and Glass Lewis, have recommended that Conatus stockholders vote “FOR” Conatus’ proposed merger with Histogen Inc. and “FOR” Conatus’ proposed reverse stock split, both of which are to be considered at Conatus’ upcoming special meeting of stockholders to be held on May 21, 2020.

Conatus Pharmaceuticals Inc. (NASDAQ: CNAT) and Histogen Inc., a privately-held regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, today announced the companies have entered into a definitive agreement under which Histogen will merge with a wholly-owned subsidiary of Conatus in an all-stock transaction.

Histogen Inc., a regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, announced the completion of its previously disclosed merger with Conatus Pharmaceuticals Inc.

Conatus Pharmaceuticals Inc. announced financial results for the fourth quarter and full year ended December 31, 2019, and provided an update on its strategic process.